Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

Siga Receives $2.3M from the U.S. Air Force

  • Siga Technologies received two contracts from the U.S. Air Force for a total of $2.3 million. A $1.4-million agreement covers the development of counter-measures against potential biowarfare pathogens, the Dengue viruses, and other water-related viral agents. Siga also won a one-year, $900,000 contract to aid the USAF Special Operations Command in its development of specific antiviral agents, focusing on orthopoxvirus targets distinct from the target that is the focus of SIGA-246, the company’s lead smallpox drug.

    Dengue fever and Dengue hemorrhagic fever are acute febrile mosquito-borne diseases caused by one of four closely related virus serotypes of the genus Flaviviridae. The two diseases affect tens of millions of people worldwide every year and present a biodefense threat in the U.S. Currently, there is no approved drug or vaccine against Dengue, leaving troops vulnerable overseas and in areas affected by flooding, according to Siga.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »